Ancillary Pharmacogenetic Studies in Heart,
Lung, Blood, and Sleep Disorders
This program focuses on the collection and utilization
of DNA from study participants, in ongoing or completed
clinical trials, to examine genetic influences on inter-individual
differences in prescription drug response. Studies under
this RFA may help elucidate basic mechanisms of drug
effects and adverse reactions and may facilitate optimal
selection of therapy in individual patients as well
as mitigating serious adverse response or lack or response
to therapy in the treatment of heart, lung, blood, and
sleep disorders. Currently, NHLBI is funding seven studies
through this mechanism.
The NHLBI Program Officer for Ancillary Pharmacogenetic
Studies is Dina
Paltoo, Ph.D., M.P.H.
The Pharmacogenetics
and Pharmacogenomics Knowledge Base
- Pharmacogenetics, Biomarkers, and Antithrombotic
Therapy (PI: Brian Gage)
- Postmenopause Chd Risk: Platelet Genes & Hormone
Therapy (PI: Paul Bray)
- Hypertension Pharmacogenetics (PI: Julie Johnson)
- Anti-Hypertensive Pharmacogenomics (PI: Stephen
Turner)
- Pharmacogenetics and Cardiovascular Events (PI:
Bruce Psaty)
- Pharmacogenetics of the Statin Response (PI: Ernst
Schaefer)
- Pharmacogenetics of Asthma Monotherapy (PI: John
Lima)
September 2003 to September 2007
Ancillary
Pharmacogenetic Studies in Heart, Lung, Blood, and Sleep
Disorders
RFA-HL-03-001 |
